Scarica l'app Stockscreener
3.09
3.13%
-0.10
Dopo l'orario di chiusura:
3.04
-0.05
-1.62%
Kiora Pharmaceuticals Inc Borsa (KPRX) Ultime notizie
Kiora Pharmaceuticals and Senju Pharmaceutical partner on KIO-301 for retinal disease treatment in Asia - Ophthalmology Times
kiora pharmaceuticals reports results of annual shareholder meeting - Investing.com
Kiora Pharmaceuticals Holds Annual Meeting, Elects Directors - TipRanks
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard SurgeMore Stocks Inside! - openPR.com
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside! - FinancialContent
ReShape Lifesciences And Kiora Pharma Impress Investors, Dollar General Uplifts Outlook - Finimize
Sector Update: Health Care - marketscreener.com
Kiora Pharmaceuticals Stock Skyrockets Over 20% in Dynamic Trading Session - Daily Chhattisgarh News
Traws Pharma Inc. Stock Skyrockets Over 40%, Then Pares Gains in Volatile Trading - Daily Chhattisgarh News
Oil Prices Climb While US Equity Futures Stutter - Finimize
Pre-market Movers: NIVF, TRAW, KKR, AGEN... - RTTNews
Kiora PharmaceuticalsEnters Exclusive Option Agreement With SenjuSEC Filing - marketscreener.com
Kiora Pharmaceuticals inks potential $110 million deal with Senju - Investing.com
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-30 - GuruFocus
Kiora Pharmaceuticals Lands $110M Asian Partnership Deal for Revolutionary Retinal Disease Treatment - Stock Titan
Kiora Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News
Q1 Earnings Estimate for KPRX Issued By HC Wainwright - Defense World
Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews
Northern Trust Strengthens Canadian Leadership: Industry Veteran Jeff Alexander Takes Helm of 150-Client Operation - Stock Titan
Persistent Epithelial Defect Market on Track for Major - openPR.com
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Kiora Pharmaceuticals Reports First Quarter Results; Initiating - GuruFocus
Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 | KPRX - GuruFocus
Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 - Stock Titan
Kiora Pharmaceuticals Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy | KPRX Stock News - GuruFocus
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy - Newsfile
May 2025 Penny Stocks With Promising Potential - simplywall.st
Kiora Pharmaceuticals (KPRX) Projected to Post Quarterly Earnings on Friday - Defense World
KPRXKIORA PHARMACEUTICALS INC Latest Stock News & Market Updates - Stock Titan
Herbal Oasis Dominates High Spirits Awards: 4 Medals for Revolutionary Hemp-Infused Drinks - Stock Titan
Corneal Epithelial Defect Therapeutics Market Size in 7MM - openPR.com
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Metagenomi Leads The Charge With These 3 Penny Stocks - simplywall.st
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference - Newsfile
Kiora Unveils Latest Progress on Two Phase 2 Retinal Disease Treatments - Stock Titan
Adagene And 2 Other Promising Penny Stocks To Watch - simplywall.st
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why - The Globe and Mail
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - Yahoo Finance
Kiora Pharmaceuticals (NASDAQ:KPRX) Earns “Buy” Rating from HC Wainwright - Defense World
Kiora Pharmaceuticals Advances Retinal Disease Pipeline - TipRanks
Kiora Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 - TradingView
Kiora Pharmaceuticals Inc expected to post a loss of 55 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals (KPRX) Expected to Announce Quarterly Earnings on Monday - Defense World
Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting - Newsfile
Breakthrough Eye Treatment: Kiora's KIO-104 Could Prevent Post-Surgery Scarring - StockTitan
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 281.5% in February - Defense World
Kiora Pharmaceuticals secures new patent for KIO-104 - MSN
Addex Therapeutics (OTCMKTS:ADDXF) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Head-To-Head Contrast - Defense World
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Growth in Short Interest - Defense World
Kiora Pharmaceuticals secures new patent for KIO-104 By Investing.com - Investing.com Nigeria
0.86%
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):